• The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • CIDP 161403

    CIDP 161403

    Enrollment Information

    Call (602) 406-6606 or E-Mail [email protected]

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia as a maintenance therapy to prevent relapse and for the treatment of CIDP. Subjects must be on a stable dosing regimen of IVIG therapy for at least 12 weeks prior to enrollment.

    For up to the first 8 weeks, subjects will continue to receive their own IVIG treatment at the same dose and frequency as prescribed prior to entry into the study. Then, subjects will be randomized to receive HyQvia administered through a subcutaneous infusion (i.e. a small needle inserted under the skin) every 2, 3, or 4 weeks for a total of 10 to 15 weeks. Overall, participants may be in the research study for about 28 weeks.

    Principal Investigator: Suraj Muley, MD

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.